A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada

Table 2 Sugammadex impact vs. neostigmine on time from patient OR admission to OR discharge, per procedure

A. Trials Requiring Verification^a of Full Neuromuscular Recovery (TOF ratio ≥ 0.9) Prior to Extubation in the OR
Sugammadex Arm		Neostigmine Arm
N	Minutes from OR admission to discharge	N	Minutes from OR admission to discharge	SugammadexTime Savings	P-value	Source
17	64	17	80	16	0.04	[16]
66 ^b	158	64	169	11	0.23	[13]
83		81		14	0.02	Meta-analysis
B. Trials Not Requiring Verification of Full Neuromuscular Recovery Prior to Extubation in the OR
Sugammadex Arm		Neostigmine Arm
N	Minutes from OR admission to discharge	N	Minutes from OR admission to discharge	SugammadexTime Savings	P-value	Source
48	183	46	167	−16	0.22	[12]
290	167	315	167	0	NA	[15]
74 ^b	242	77	253	11	0.40	[14]
412		438		−1	0.89	Meta-analysis

NA Not applicable OR Operating room, TOF Train-of-four
^aVerification of full neuromuscular recovery (TOF ratio ≥ 0.9) based on quantitative neuromuscular monitoring
^bNumbers below this row reflect a pooling of data via meta-analysis

ISSN: 1471-2253